Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 606


Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.

Lancet Oncol. 2018 Mar 9. pii: S1470-2045(18)30107-4. doi: 10.1016/S1470-2045(18)30107-4. [Epub ahead of print]


Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.

Diana P, Mankongpaisarnrung C, Atkins MB, Zeck JC, Charabaty A.

ACG Case Rep J. 2018 Feb 28;5:e17. doi: 10.14309/crj.2018.17. eCollection 2018.


Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Tannir NM, Pal SK, Atkins MB.

Oncologist. 2018 Feb 27. pii: theoncologist.2017-0534. doi: 10.1634/theoncologist.2017-0534. [Epub ahead of print] Review.


Correction to: The Effect of a Change Agent on Use of Evidence-Based Mental Health Practices.

Leathers SJ, Spielfogel JE, Blakey J, Christian E, Atkins MS.

Adm Policy Ment Health. 2018 Feb 24. doi: 10.1007/s10488-018-0859-9. [Epub ahead of print]


Large inter-rater variability on EEG-reactivity is improved by a novel quantitative method.

Duez CHV, Ebbesen MQ, Benedek K, Fabricius M, Atkins MD, Beniczky S, Kjaer TW, Kirkegaard H, Johnsen B.

Clin Neurophysiol. 2018 Apr;129(4):724-730. doi: 10.1016/j.clinph.2018.01.054. Epub 2018 Feb 2.


Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA.

J Clin Oncol. 2018 Feb 14:JCO2017776385. doi: 10.1200/JCO.2017.77.6385. [Epub ahead of print]


Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE, Tarazi JC, Rosbrook B, Fernandez KC, Lechuga M, Choueiri TK.

Lancet Oncol. 2018 Mar;19(3):405-415. doi: 10.1016/S1470-2045(18)30081-0. Epub 2018 Feb 10.


Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9.


Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.

Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A.

Clin Cancer Res. 2018 Jan 22. doi: 10.1158/1078-0432.CCR-17-3436. [Epub ahead of print]


Update on the Integrated Nutrition Pathway for Acute Care (INPAC): post implementation tailoring and toolkit to support practice improvements.

Keller H, Laur C, Atkins M, Bernier P, Butterworth D, Davidson B, Hotson B, Nasser R, Laporte M, Marcell C, Ray S, Bell J.

Nutr J. 2018 Jan 5;17(1):2. doi: 10.1186/s12937-017-0310-1.


Trends in Children's Mental Health Services Research Funding by the National Institute of Mental Health From 2005 to 2015: A 42% Reduction.

Hoagwood KE, Atkins M, Kelleher K, Peth-Pierce R, Olin S, Burns B, Landsverk J, Horwitz SM.

J Am Acad Child Adolesc Psychiatry. 2018 Jan;57(1):10-13. doi: 10.1016/j.jaac.2017.09.433. No abstract available.


Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.


Sit Down and Play: A Preventive Primary Care-Based Program To Enhance Parenting Practices.

Shah R, DeFrino D, Kim Y, Atkins M.

J Child Fam Stud. 2017 Feb;26(2):540-547. doi: 10.1007/s10826-016-0583-6. Epub 2016 Oct 18.


Thoracic Surgery Considerations in the Child and Young Adult.

Atkins MD, Fuller S.

Thorac Surg Clin. 2018 Feb;28(1):43-52. doi: 10.1016/j.thorsurg.2017.08.005. Epub 2017 Oct 18. Review.


A Response to Proposed Budget Cuts Affecting Children's Mental Health: Protecting Policies and Programs That Promote Collective Efficacy.

Hoagwood KE, Atkins M, Horwitz S, Kutash K, Olin SS, Burns B, Peth-Pierce R, Kuppinger A, Burton G, Shorter P, Kelleher KJ.

Psychiatr Serv. 2018 Mar 1;69(3):268-273. doi: 10.1176/ Epub 2017 Nov 1.


Indoor Tanning Dependence in Young Adult Women.

Mays D, Atkins MB, Ahn J, Tercyak KP.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1636-1643. doi: 10.1158/1055-9965.EPI-17-0403. Epub 2017 Oct 19.


Societal preferences for adjuvant melanoma health states: UK and Australia.

Middleton MR, Atkins MB, Amos K, Wang PF, Kotapati S, Sabater J, Beusterien K.

BMC Cancer. 2017 Oct 17;17(1):689. doi: 10.1186/s12885-017-3673-y.


Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M.

J Clin Oncol. 2018 Feb 1;36(4):391-398. doi: 10.1200/JCO.2017.72.2850. Epub 2017 Oct 17.


Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.

Atkins M, Coutinho AD, Nunna S, Gupte-Singh K, Eaddy M.

J Med Econ. 2018 Feb;21(2):212-217. doi: 10.1080/13696998.2017.1391818. Epub 2017 Oct 30.


High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE.

Cancer Med. 2017 Nov;6(11):2576-2585. doi: 10.1002/cam4.1223. Epub 2017 Oct 10.


Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD.

J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.


Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators.

N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.


Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS.

Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.


A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.

Izar B, Sharfman W, Hodi FS, Lawrence D, Flaherty KT, Amaravadi R, Kim KB, Puzanov I, Sosman J, Dummer R, Goldinger SM, Lam L, Kakar S, Tang Z, Krieter O, McDermott DF, Atkins MB.

Cancer Med. 2017 Aug;6(8):1904-1914. doi: 10.1002/cam4.1140. Epub 2017 Jul 18.


Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

Butterfield LH, Zhao F, Lee S, Tarhini AA, Margolin KA, White RL, Atkins MB, Cohen GI, Whiteside TL, Kirkwood JM, Lawson DH.

Clin Cancer Res. 2017 Sep 1;23(17):5034-5043. doi: 10.1158/1078-0432.CCR-16-3016. Epub 2017 May 23.


Lifestyle intervention for adults with spinal cord injury: Results of the USC-RLANRC Pressure Ulcer Prevention Study.

Carlson M, Vigen CL, Rubayi S, Blanche EI, Blanchard J, Atkins M, Bates-Jensen B, Garber SL, Pyatak EA, Diaz J, Florindez LI, Hay JW, Mallinson T, Unger JB, Azen SP, Scott M, Cogan A, Clark F.

J Spinal Cord Med. 2017 Apr 17:1-18. doi: 10.1080/10790268.2017.1313931. [Epub ahead of print]


Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.

Atkins MB, Clark JI, Quinn DI.

Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151. Review.


Schooling and Children's Mental Health: Realigning Resources to Reduce Disparities and Advance Public Health.

Atkins MS, Cappella E, Shernoff ES, Mehta TG, Gustafson EL.

Annu Rev Clin Psychol. 2017 May 8;13:123-147. doi: 10.1146/annurev-clinpsy-032816-045234. Epub 2017 Mar 24. Review.


Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.

Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK.

JAMA Oncol. 2017 Sep 1;3(9):1249-1252. doi: 10.1001/jamaoncol.2017.0076.


Hybrid aortic arch surgery: Have we reached clinical equipoise?

Atkins MD, Szeto WY.

J Thorac Cardiovasc Surg. 2017 Jul;154(1):98-99. doi: 10.1016/j.jtcvs.2017.01.026. Epub 2017 Feb 2. No abstract available.


The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma.

Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF, Atkins MB, Byers SW, Rosenthal DS.

Oncotarget. 2017 Feb 21;8(8):12576-12595. doi: 10.18632/oncotarget.14990.


Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.


Intermolecular structure and hydrogen-bonding in liquid 1,2-propylene carbonate and 1,2-glycerol carbonate determined by neutron scattering.

Delavoux YM, Gilmore M, Atkins MP, Swadźba-Kwaśny M, Holbrey JD.

Phys Chem Chem Phys. 2017 Jan 25;19(4):2867-2876. doi: 10.1039/c6cp07790k.


The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.

Voss MH, Bhatt RS, Plimack ER, Rini BI, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins MB.

Clin Cancer Res. 2017 Jul 15;23(14):3557-3565. doi: 10.1158/1078-0432.CCR-16-2395. Epub 2016 Dec 28.


Assessing the recharge of a coastal aquifer using physical observations, tritium, groundwater chemistry and modelling.

Santos IR, Zhang C, Maher DT, Atkins ML, Holland R, Morgenstern U, Li L.

Sci Total Environ. 2017 Feb 15;580:367-379. doi: 10.1016/j.scitotenv.2016.11.181. Epub 2016 Dec 15.


Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Gibney GT, Weiner LM, Atkins MB.

Lancet Oncol. 2016 Dec;17(12):e542-e551. doi: 10.1016/S1470-2045(16)30406-5. Review.


Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81. eCollection 2016.


[Cognitive deficits are underestimated in children with benign epilepsy with centro-temporal spikes].

Atkins MD, Juul K.

Ugeskr Laeger. 2016 Nov 7;178(45). pii: V04160249. Danish.


FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.

Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Mier JW, Panka DJ, McDermott DF, Sondel PM.

Clin Cancer Res. 2017 May 1;23(9):2159-2168. doi: 10.1158/1078-0432.CCR-16-1874. Epub 2016 Oct 14.


The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA.

Cancer. 2016 Nov 15;122(21):3354-3362. doi: 10.1002/cncr.30259. Epub 2016 Aug 17.


Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.

Wang W, Erbe AK, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM.

Cancer Immunol Immunother. 2016 Dec;65(12):1523-1532. Epub 2016 Sep 30.


Seasonal exports and drivers of dissolved inorganic and organic carbon, carbon dioxide, methane and δ13C signatures in a subtropical river network.

Atkins ML, Santos IR, Maher DT.

Sci Total Environ. 2017 Jan 1;575:545-563. doi: 10.1016/j.scitotenv.2016.09.020. Epub 2016 Sep 28.


Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases.

Rapisuwon S, Busam KJ, Parks K, Chapman PB, Lee E, Atkins MB.

Am J Dermatopathol. 2016 Sep;38(9):687-9. doi: 10.1097/DAD.0000000000000660.


Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).

Atkins MB, Philips GK.

Expert Opin Emerg Drugs. 2016 Sep;21(3):243-54. doi: 10.1080/14728214.2016.1226798. Review.


Support for indoor tanning policies among young adult women who indoor tan.

Mays D, Murphy SE, Bubly R, Atkins MB, Tercyak KP.

Transl Behav Med. 2016 Dec;6(4):613-621.


An Ectopic Network of Transcription Factors Regulated by Hippo Signaling Drives Growth and Invasion of a Malignant Tumor Model.

Atkins M, Potier D, Romanelli L, Jacobs J, Mach J, Hamaratoglu F, Aerts S, Halder G.

Curr Biol. 2016 Aug 22;26(16):2101-13. doi: 10.1016/j.cub.2016.06.035. Epub 2016 Jul 28.


Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK.

J Natl Compr Canc Netw. 2016 Jul;14(7):820-4.


What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?

Atkins MB.

Clin Adv Hematol Oncol. 2016 Jun;14(6):417-9. No abstract available.


Authors' reply.

Kirov G, Atkins M.

Br J Psychiatry. 2016 Jul;209(1):84-5. doi: 10.1192/bjp.209.1.84a. No abstract available.


Supplemental Content

Loading ...
Support Center